

# References

1. Barr PM, et al. Final analysis from RESONATE: 6-year follow-up in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma on ibrutinib. Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting; 31 May-4 June 2019; Chicago, IL, USA.
2. Fraser G, et al. Final 5-year updated results from a Phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Poster presented at the XVIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL) meeting, September 20-23, 2019, Edinburgh, Scotland. #2021.
3. O'Brien SM, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. *Lancet Oncol* 2016;17(10):1409-1418.
4. Byrd JC, et al. Up to 7 years of follow-up of single-agent ibrutinib in the phase 1b/2 PCYC-1102 trial of first-line and relapsed/refractory patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Poster presented at the 60th ASH Annual Meeting & Exposition; 1-4 December 2018; San Diego, CA, USA.
5. Burger JA, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. *Leukemia* 2019 [Epub ahead of print].
6. Woyach JA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. *N Eng J Med* 2018;379(26):2517-2528.
7. Moreno C, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab as first-line treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: up to 4 years of extended follow-up from the phase 3 iLLUMINATE study. Poster presented at the XVIII International Workshop on CLL (iwCLL) Meeting; 20-23 September 2019; Edinburgh, Scotland. #2069.
8. Rule S, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. *Leukemia* 2018;32(8):1799-1803.
9. Rule S, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: Extended 3.5-year follow-up from a pooled analysis. *Haematologica* 2019;104(5):e211-e214.
10. Treon SP, et al. Ibrutinib monotherapy produces long-term disease control in previously treated Waldenström's macroglobulinemia. Final report of the pivotal trial. *Haem Onc* 2019;37(S2):184-185.
11. Buske C, et al. Ibrutinib treatment in Waldenström's macroglobulinemia: follow-up efficacy and safety from the iNOVATETM study. Oral presentation at the 60th ASH Annual Meeting & Exposition; 1-4 December 2018; San Diego, CA, USA.
12. IMBRUVICA® UK Summary of Product Characteristics. Janssen-Cilag Limited. August 2020.
13. Janssen Data on File. Ibrutinib - global number of cumulative patients treated with Ibrutinib since launch. July 2020
14. Janssens A, et al. Effectiveness and safety of ibrutinib for chronic lymphocytic leukemia (CLL) in routine clinical practice: interim analysis (IA) of the Belgian ibrutinib real-world data (BiRD) study. *HaemaSphere* 2019;3:144.
15. Byrd J.C. et al. 2020. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase 1b/2 PCYC-1102 Study. *Clinical Cancer Research* 2020, [Accepted Manuscript] DOI:10.1158/1078-0432.CCR-19-2856